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Background: The recently postulated “disease spreading hypothesis” has gained much 
attention, especially for Parkinson’s disease (PD). The various non-motor symptoms 
(NMS) in neurodegenerative diseases would be much better explained by this hypothe-
sis than by the degeneration of disease-specific cell populations. Motor neuron disease 
(MND) is primarily known as a group of diseases with a selective loss of motor function. 
However, recent evidence suggests disease spreading into non-motor brain regions also 
in MND. The aim of this study was to comprehensively detect NMS in patients suffering 
from MND.
Methods: We used a self-rating questionnaire including 30 different items of gastro-
intestinal, autonomic, neuropsychiatric, and sleep complaints [NMS questionnaire 
(NMSQuest)], which is an established tool in PD patients. 90 MND patients were included 
and compared to 96 controls.
results: In total, MND patients reported significantly higher NMS scores (median: 7 
points) in comparison to controls (median: 4 points). Dribbling, impaired taste/smelling, 
impaired swallowing, weight loss, loss of interest, sad/blues, falling, and insomnia were 
significantly more prevalent in MND patients compared to controls. Interestingly, exces-
sive sweating was more reported in the MND group. Correlation analysis revealed an 
increase of total NMS score with disease progression.
conclusion: NMS in MND patients seemed to increase with disease progression, which 
would fit with the recently postulated “disease spreading hypothesis.” The total NMS 
score in the MND group significantly exceeded the score for the control group, but only 
8 of the 30 single complaints of the NMSQuest were significantly more often reported 
by MND patients. Dribbling, impaired swallowing, weight loss, and falling could primarily 
be connected to motor neuron degeneration and declared as motor symptoms in MND.
Keywords: amyotrophic lateral sclerosis, motor neuron disease, nMsQuest, non-motor symptoms, multisystem 
disorder
Abbreviations: χ2, chi-squared test; ALSFRS-R, revised ALS-Functional-Rating-Scale; FTD, frontotemporal dementia; MND, 
motoneuron disease; MNDwbs, MND patients without bulbar symptoms; MWU, Mann–Whitney U-test; NMS, non-motor 
symptoms; PD, Parkinson’s disease.
TaBle 1 | Demographic and clinical characteristics of the study 
populations.
control group MnD group
Total number 96 90
Ratio of females in % 52.1 50.0
Age in years 65.3 ± 10.5 65.1 ± 10.5
Disease duration in years – 3 ± 2.3
ALS-FRS-R (range) – 30 (8–46)
Subtypes (n) – Spinal onset (53)
Bulbar onset (26)
Primary lateral sclerosis (11)
Bulbar symptoms in % – 66.7
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inTrODUcTiOn
Motor neuron diseases (MND), such as amyotrophic lateral 
sclerosis, are neurodegenerative diseases with a progressive 
degeneration of motor neurons and their axons. Consecutive loss 
of motor function like paralysis of extremities and impairment of 
the respiratory apparatus are the cardinal symptoms. For many 
neurodegenerative diseases, it is well known that the pathology 
is not limited to the initially affected cell populations. Instead, 
disease spreading and involvement of other non-motor regions in 
the brain seem to occur (1). Corresponding non-motor symptoms 
(NMS) like gastrointestinal-, autonomic-, neuropsychiatric-, and 
sleep disorders are well known in these diseases. Treatments of 
such NMS are fundamental elements in a modern and compre-
hensive health care for patients suffering from neurodegenerative 
diseases (2, 3).
Frequently reported comorbidity with frontotemporal demen-
tia (FTD), autonomic dysfunctions like delayed gastric emptying 
and colonic transit times, small-fiber neuropathy, pain as well as 
abnormalities in extra-motor areas in functional brain imaging 
studies make it justified to classify also MND as multisystem 
disorders (4–10). Moreover, recent neuropathology studies 
showed disease spreading also in MND and FTD, suggesting 
the involvement of non-motor regions in the pathophysiology of 
these disorders (11–13).
The aim of this study was to investigate the appearance of NMS 
in MND by comparing their prevalence to age- and sex-matched 
healthy individuals using the NMS questionnaire (NMSQuest). 
Although the NMSQuest was designed and validated for 
Parkinson’s disease (PD) (2), this questionnaire with its 30 items 
represents a suitable screening tool for NMS in MND.
PaTienTs anD MeThODs
Patients
Patients with definite, probable, or possible amyotrophic lateral 
sclerosis, according to the revised El Escorial criteria (14, 15), as 
well as patients with primary lateral sclerosis, were recruited from 
2012 to 2015 at the Department of Neurology of the University 
Hospital Dresden. Patients suffering from genetic variants of spi-
nal muscular atrophy, spinal bulbar muscular atrophy, and FTD 
overlap syndromes were not included. Additionally, age- and sex-
matched controls were recruited from several centers (Europe, 
USA, and Japan) who participated in the NMSQuest study (3). 
The study was approved by the institutional review board at the 
Technische Universität Dresden (EK 393122012, EK 49022016). 
The initial ethical approval was obtained by the research ethics 
committee at the University Hospital Lewisham and subsequently 
all involved centers obtained site-specific ethical approvals.
assessments
The NMSQuest is a 30-item self-completed questionnaire featur-
ing responses as “yes” and “no” to each item and was originally 
designed and validated for PD patients (2, 3, 16). These 30 items 
can be grouped into 9 domains (digestive, urinary, memory, per-
ceptions, mood, sex, cardiovascular, sleep, and miscellaneous), 
as previously described (2, 3). “Total NMS score” was defined by 
the calculated sum of all positive (“yes”) answers of the 30 items. 
We additionally recorded age, gender, current symptoms with a 
special focus on bulbar symptoms, MND subtype, vital capacity, 
body weight, disease duration, and the revised ALS-Functional-
Rating-Scale (ALSFRS-R). A sub-cohort was retested after a 
period of 6 ± 3 months.
statistical analysis
As the samples were not normally distributed, statistical 
comparisons of data between groups were made using the non-
parametric Mann–Whitney U-test (MWU) for total NMS score, 
NMS domains, and age. The chi-squared test (χ2) was carried out 
for a comparison of gender distribution and for a comparison of 
the proportion of “yes” and “no” responses  between patients and 
controls for each single item. Spearman rank correlation coef-
ficients were used to examine correlations between total NMS 
score and demographic as well as clinical data in the MND group 
with a correlation coefficient of rho < 0.3 considered as a weak, 
rho = 0.3–0.59 a moderate, and rho ≥ 0.6 a strong correlation. 
Data were analyzed using the software programs SPSS 21.0 (SPSS 
Inc., Chicago, IL, USA) and Statistica 12.0 [StatSoft (Europe) 
GmbH, Hamburg, Germany]. If not mentioned otherwise, all data 
are displayed as means ± SD. Significance level was set at p < 0.05. 
Correction for multiple testing was not applied as the study was 
merely exploratory, and a previous hypothesis was not proposed.
resUlTs
NMSQuest data from 90 MND patients and 96 controls were ana-
lyzed and compared. Demographic and clinical characteristics of 
the NMS study populations are shown in Table 1. The two groups 
did not differ significantly in age (MWU p = 0.87) or gender (χ2 
p = 0.78).
Motor neuron disease patients reported significantly more 
NMS in total compared to healthy individuals (Figure 1A). The 
sum of NMS ranged from 1 to 18 with median 7 for MND patients 
and from 0 to 19 in the control group with median 4 (MWU 
p < 0.0001).
Comparisons on the NMS domain level showed significantly 
higher scores for MND patients in the domains “digestive” (MND: 
1.98 ± 1.54; control: 0.97 ± 1.26; MWU p < 0.00001), “mood” 
(MND: 0.70 ± 0.79; control: 0.42 ± 0.71; MWU p < 0.01), and 
“cardiovascular” (MND: 0.61 ± 0.67; control: 0.28 ± 0.56; MWU 
p < 0.001).
FigUre 1 | comparison of total nMs score (a) and single items (B) of the nMsQuest between controls (white) and MnD patients (black) depicted as 
box plot and histograms, respectively. Correlation of total NMS score and ALSFRS-R is shown as scatterplot (c). Spearman rank correlation coefficient (rho), 
*p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, #p < 0.06 (trend).
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On the single-item level, MND patients reported significantly 
more dribbling, impaired taste/smelling, impaired swallowing, 
weight loss, loss of interest, sad/blues, falling, and insomnia. 
Excessive sweating was 11% more often reported in the MND 
group compared to the control group. The items pain and remem-
bering were significantly less reported by MND patients. Detailed 
statistics are presented in Table 2 and Figure 1B.
Since some of the above mentioned NMS (swallowing, 
dribbling, and taste/smelling) could be due to bulbar paresis, 
we separately analyzed these items in MND patients without 
bulbar symptoms (MNDwbs). By doing so, there were no 
longer any significant difference to controls regarding dribbling 
(MNDwbs: 6.7%; control: 7.3%; χ2 p = 0.9) and impaired taste/
smelling (MNDwbs: 16.7%, control: 7.3%; χ2 p = 0.12). However, 
significantly more patients in the “MNDwbs” group complained 
about impaired swallowing as compared to the control group 
(MNDwbs: 26.7%; control: 10.4%; χ2 p = 0.02).
Correlation analysis of total NMS score to clinical and demo-
graphic data revealed a moderate correlation with ALS-FRS-R 
(rho = −0.42, p = 0.00005) (Figure 1C) and a weak correlation 
with age (rho = 0.24, p = 0.03) and vital capacity (rho = −0.27, 
p = 0.02).
Follow-up data after 6 ± 3 months of 43 MND patients showed 
an increase of total NMS score (0.95 ± 2.64). The increase of total 
NMS score correlated with the decrease of ALS-FRS-R (rho = 0.34, 
p = 0.03) and the decrease of vital capacity (rho = 0.39, p = 0.03).
DiscUssiOn anD cOnclUsiOn
Non-motor symptoms are very common in PD and other neu-
rodegenerative disorders (2, 3, 17). Frontotemporal impairment 
and memory loss are commonly known as “non-motor” involve-
ments in MND patients. Besides that, multiple other extra-motor 
symptoms in MND have been reported in the last years (18), for 
example, autonomic dysfunctions (4, 19–21), sensory symptoms 
due to distal small-fiber neuropathy (5), and pain (6–8). However, 
this is the first pilot study for a comprehensive detection of NMS 
in MND patients.
Dribbling, impaired taste/smelling, impaired swallowing, 
weight loss, loss of interest, sad/blues, falling, excessive sweating, 
TaBle 2 | comparison of responses between controls and MnD patients.
Distribution of response “yes” 
in percentages
chi-squared-
test
control group MnD group For yes–no
Dribbling 7.3 41.1 0.00000
Taste/smelling 7.3 21.1 0.0066
Swallowing 10.4 65.6 0.00000
Vomiting 15.6 10.0 0.25
Constipation 26.0 25.6 0.94
Bowel incontinence 9.4 7.8 0.69
Bowel emptying 20.8 26.7 0.35
Urgency 45.8 51.1 0.47
Nocturia 60.4 50.0 0.15
Pains 30.2 17.8 0.048
Weight loss 6.3 21.1 0.003
Remembering 33.3 13.3 0.001
Loss of interest 12.5 26.7 0.015
Hallucinations 2.1 0.0 n.c.
Concentration 18.8 23.3 0.44
Sad, blues 26.0 46.7 0.003
Anxiety 15.6 23.3 0.18
Sex drive 24.0 23.3 0.92
Sex difficulty 16.7 24.4 0.19
Dizzy 20.8 18.9 0.74
Falling 7.3 42.2 0.00000
Daytime sleepiness 9.4 10.0 0.86
Insomnia 31.3 48.9 0.014
Intense vivid dreams 8.3 12.2 0.38
Acting out during dreams 10.4 6.7 0.36
Restless legs 28.1 30.0 0.77
Swelling 27.1 27.8 0.92
Excessive sweating 13.5 24.4 0.057
Diplopia 4.2 0.0 n.c.
Delusions 2.1 0.0 n.c.
n.c, non-calculable.
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and insomnia were found to be prominent complaints in MND 
patients compared to controls. Dribbling, impaired swallowing, 
weight loss, and falling could be primarily discussed as motor 
symptoms. In line with that, dribbling was reported with equal 
frequency by MNDwbs compared to controls in the current study. 
Investigations in salivary gland function revealed saliva flow rate 
alterations, but these abnormalities were mild in contrast to the 
relevant problem of dribbling in MND patients suggesting that this 
symptom primarily is a consequence of bulbar motor impairment 
(20). Nevertheless, swallowing was still reported significantly 
more often by MND patients without clinically detectable bulbar 
symptoms. Presumably, subjective impairment of the swallowing 
act exists in some patients before bulbar symptoms are observed 
in clinical examination.
Taste/smelling complaints were significantly more reported, 
however only in patients suffering from bulbar symptoms. 
Hyposmia and hyperechogenic substantia nigra are well-known 
predictive markers for PD (22). Interestingly, hyperechogenicity 
of the substantia nigra was recently reported also in MND (23, 24). 
Thus, future studies regarding hyposmia in MND are of interest 
for interpreting possible similarities to PD. To our knowledge, 
large case–control studies with diagnostic tests for hyposmia in 
MND have not been previously reported.
Insomnia could be regarded as NMS but could partly be due to 
insufficient respiratory function during sleep and could therefore 
be discussed as a motor symptom. As confirmed by our results, 
affection of mood is a well-known problem in the treatment of 
MND patients (25–27). Moreover, we found excessive sweat-
ing increased in the patients as compared to the controls. This 
fits to recent data showing abnormal sympathetic activity with 
hyperhidrosis in early MND and a reduction in sweat production 
with disease progression (28). Pain was significantly less reported 
in our study. Detailed and specific pain questionnaires already 
revealed the relevant impact of pain in MND (6–8), but pain in 
these patients is mostly a result of immobility, muscle atrophy as 
well as increased muscle tone and could be due to motor neuron 
degeneration. The question about pain in the NMSQuest aimed 
at “unexplained pain,” which could be confusing and lead to a 
false negative answer. Furthermore, the diversity of pain may not 
be answered in a single question. Thus, pain in the domain of 
NMS needs future investigation. The item impaired remembering 
was significantly less common in the MND group in our study, 
whereas an increased frequency of cognitive impairment has 
previously been shown in MND patients (29).
Previous investigations have suggested that quality of life in 
MND is not strongly related to the level of physical impairment 
and that MND patients displace their focus away from decreasing 
health status (30, 31). These coping mechanisms possibly reduce 
the self-perception of NMS in MND patients. We therefore can-
not exclude that some of the items, which do not differ between 
the patient and control group in our study, can be relevant after 
detailed interview. Future studies with objective measurement 
methods are therefore necessary.
To summarize, the total amount of NMS among the MND 
patients exceeded the amount of such symptoms in the control 
group. The single-item analysis revealed relevant complaints in 
MND patients, and the total NMS score seemed to increase with 
disease progression. However, comparing total NMS of MND 
patients with the already published data of PD patients, the impact 
of NMS in MND (median 7) turned out to be less pronounced 
than in PD (median 9) (2). On the single-item level, the PD 
group reported more complaints in 16 different items compared 
to controls, while for MND, we only detected significant differ-
ences for 8 items. Additionally, the most prominent items drib-
bling, impaired swallowing, weight loss, and falling are primarily 
caused by degeneration of the motor neurons. Nevertheless, NMS 
seem to increase with disease progression, which would fit with 
recently published neuropathological data, suggesting spreading 
of disease with widespread neuropathology at advanced stages 
(11–13). Therefore, it would be of great interest to perform 
another study on the frequency of NMS in a group of patients 
representing advanced MND disease stages. Finally, we strongly 
believe that assessment and treatment of NMS should be included 
in a modern and comprehensive health care of MND patients.
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